Andrew Tsai
Stock Analyst at Jefferies
(0.84)
# 3,942
Out of 5,050 analysts
25
Total ratings
40%
Success rate
-18.18%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVDL Avadel Pharmaceuticals | Downgrades: Hold | $22 → $20 | $18.69 | +7.01% | 1 | Oct 22, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $300 | $168.22 | +78.34% | 1 | Oct 16, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Hold | $75 → $56 | $54.04 | +3.63% | 1 | Oct 9, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $155.51 | +22.18% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $17.63 | +98.53% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $22.86 | +31.23% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $61.80 | +13.27% | 1 | Jul 14, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $3.17 | -21.14% | 2 | May 28, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $200 | $138.15 | +44.77% | 1 | Apr 7, 2025 | |
| BEKE KE Holdings | Maintains: Overweight | $19 → $27 | $15.60 | +73.08% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $2.65 | +390.57% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $25.66 | +36.40% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $11.55 | +185.71% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $0.2 → $15 | $3.99 | +275.94% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.25 | +140.00% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $320 → $30 | $3.85 | +679.22% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $4.36 | +519.27% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $38.25 | -39.87% | 1 | Jun 1, 2020 |
Avadel Pharmaceuticals
Oct 22, 2025
Downgrades: Hold
Price Target: $22 → $20
Current: $18.69
Upside: +7.01%
Praxis Precision Medicines
Oct 16, 2025
Maintains: Buy
Price Target: $65 → $300
Current: $168.22
Upside: +78.34%
Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $75 → $56
Current: $54.04
Upside: +3.63%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $155.51
Upside: +22.18%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $17.63
Upside: +98.53%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $22.86
Upside: +31.23%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $61.80
Upside: +13.27%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.17
Upside: -21.14%
Axsome Therapeutics
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $138.15
Upside: +44.77%
KE Holdings
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $15.60
Upside: +73.08%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $2.65
Upside: +390.57%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $25.66
Upside: +36.40%
Feb 27, 2024
Initiates: Buy
Price Target: $33
Current: $11.55
Upside: +185.71%
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $3.99
Upside: +275.94%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.25
Upside: +140.00%
Jun 23, 2022
Downgrades: Hold
Price Target: $320 → $30
Current: $3.85
Upside: +679.22%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $4.36
Upside: +519.27%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $38.25
Upside: -39.87%